Skip to search formSkip to main contentSkip to account menu

PF 04929113

Known as: SNX-5422 Mesylate, PF04929113, SNX-5422 
The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzamidesIndazoles
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Small Molecules Identified from a Quantitative Drug Combinational Screen Resensitize Cisplatin's Response in Drug-Resistant Ovarian Cancer Cells
2017
2017
A phase 1B study of SNX-5422 plus carboplatin (C) and paclitaxel (P) in patients with advanced non-small-cell lung cancer (NSCLC).
e20622Background: SNX-5422 is an orally bioavailable pro-drug of SNX-2112, a highly potent and selective heat shock protein (Hsp… 
2013
2013
Results of two phase I dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422.
2617 Background: SNX-5422 is a prodrug of SNX-2112, a highly potent, non-geldanamycin analog, HSP90 inhibitor with preclinical… 
2013
2013
Kinases Essential for Male Fertility Serine / Threonine Kinases , a Family of Stabilize and Activate the Testis-specific Heat Shock Protein 90 Functions to Signal Transduction :
2012
2012
Overcoming poor permeability - the role of prodrugs for oral drug delivery.
  • H. Maag
  • Drug Discovery Today : Technologies
  • 2012
  • Corpus ID: 13277319
2010
2010
Determination of PF-04928473 in human plasma using liquid chromatography with tandem mass spectrometry.
2009
2009
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Inhibition of Hsp90 has emerged as a therapeutic strategy to target NSCLC subtypes, which are refractory to epidermal growth… 
2009
2009
Cancer Therapy : Preclinical CUDC-305 , a Novel Synthetic HSP 90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Purpose:We designed and synthesized CUDC-305, an HSP90 inhibitor of the novel imidazopyridine class. Here, we report its unique… 
2008
2008
A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
14613 Background: SNX-5422 is an oral pro-drug of SNX-2112, a potent and highly selective small-molecule inhibitor of the… 
2006
2006
A novel, selective, orally active, potent small molecule inhibitor of Hsp90.
13067 Background: The preclinical and clinical data evaluating derivatives of the natural product geldanamycin, including 17-AAG… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)